Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Respiratory Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,780 result(s) found for: Respiratory Disease. Displaying page 35 of 139.
    «« First « Previous 31  32  33  34  35  36  37  38  39  Next» Last»»
    EudraCT Number: 2009-013163-18 Sponsor Protocol Number: R014 Start Date*: 2009-08-11
    Sponsor Name:REVOTAR Biopharmaceuticals AG
    Full Title: A double-blind, placebo controlled, randomized, cross-over Phase IIa study to evaluate the effect of Bimosiamose on ozone induced sputum neutrophilia in healthy subjects.
    Medical condition: healthy subjects
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    9.1 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002664-73 Sponsor Protocol Number: GALACTIC-1 Start Date*: 2020-05-25
    Sponsor Name:Galecto Biotech AB
    Full Title: GALACTIC-1- A randomized, double-blind, multicentre, parallel, placebo-controlled Phase 2b study in subjects with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of GB0139...
    Medical condition: Patients with idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10067761 Exacerbation of idiopathic pulmonary fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) PL (Completed) ES (Ongoing) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-013235-38 Sponsor Protocol Number: CQVA149A2307 Start Date*: 2010-03-25
    Sponsor Name:Novartis Pharma AG
    Full Title: A multicenter, randomized, double-blind, placebocontrolled study, to assess the long term safety of 52 weeks treatment with QVA149 (110μg indacaterol / 50μg glycopyrrolate) in patients with moderat...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) GB (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005413-23 Sponsor Protocol Number: CY4031 Start Date*: 2016-05-20
    Sponsor Name:Cytokinetics, Inc.
    Full Title: A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients with Amyotroph...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IE (Completed) NL (Completed) ES (Completed) PT (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006886-10 Sponsor Protocol Number: M/34273/23 Start Date*: 2009-02-16
    Sponsor Name:Laboratorios Almirall, S.A.
    Full Title: A multiple dose, double blind, double-dummy, two-week 3 way cross-over, placebo-controlled clinical trial to assess the efficacy and safety of twice daily inhaled Aclidinium-bromide 400 µg compared...
    Medical condition: patients with stable moderate to severe chronic obstructive pulmonary disease (COPD) will be included.
    Disease: Version SOC Term Classification Code Term Level
    11.1 10009033 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003169-42 Sponsor Protocol Number: 1249.1 Start Date*: 2007-11-30
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: A Randomised, Phase II, Double-Blind, Double-Dummy, four-period Crossover Efficacy and Safety Comparison of 4-Week Treatment Periods of Blinded Fluticasone (500 μg bid, MDI), Ciclesonide (400 μg qd...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) DK (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001953-28 Sponsor Protocol Number: EFC15804 Start Date*: 2019-07-01
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstr...
    Medical condition: Chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) DK (Completed) FI (Completed) CZ (Completed) HU (Completed) PL (Completed) SK (Completed) BG (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-010621-39 Sponsor Protocol Number: Start Date*: 2009-06-30
    Sponsor Name:Comité Départemental d’Hygiène Social
    Full Title: Apport de l’Hélium dans le réentraînement à l’effort des patients atteints de broncho-pneumopathie chronique obstructive sévère. Etude prospective en double aveugle randomisée. Mélange hélium-oxygè...
    Medical condition: réentraînement à l’effort des patients atteints de bronchopneumopathies obstructives sévères
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022901-16 Sponsor Protocol Number: TRAMA Start Date*: 2011-07-28
    Sponsor Name:Gemma Rialp
    Full Title: Estudio multicéntrico sobre el efecto del tratamiento de la alcalosis metabólica con acetazolamida en la duración de la ventilación mecánica.
    Medical condition: Enfermedad pulmonar obstructiva crónica y síndrome de obesidad ventilación
    Disease: Version SOC Term Classification Code Term Level
    13 10009725 EPOC LLT
    13 10064205 Síndrome de obesidad-hipoventilación LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-003153-90 Sponsor Protocol Number: P061011 Start Date*: 2007-10-31
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Traitement par érythropoïétine de l'anémie associée à la bronchopneumopathie chronique obstructive : conséquences fonctionnelles à l'effort
    Medical condition: Anémie associée à la BPCO
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009033 chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014416-35 Sponsor Protocol Number: 1222.38 Start Date*: 2010-01-22
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: Randomised, double-blind, placebo-controlled, 3-way cross-over study to determine the effect of 6 weeks treatment of orally inhaled BI 1744 CL (5 µg [2 actuations of 2.5µg] and 10 µg [2 actuations...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014880-38 Sponsor Protocol Number: 1237.18 Start Date*: 2009-12-14
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: A randomised, double-blind, 8 treatments, 4 periods, incomplete crossover study to determine the optimal free dose combination of BI 1744 CL and tiotropium bromide (both delivered by the Respimat® ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014395-21 Sponsor Protocol Number: 1222.37 Start Date*: 2010-02-08
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Randomised, double-blind, placebo-controlled, 3-way cross-over study to determine the effect of 6 weeks treatment of orally inhaled BI 1744 CL (5 µg [2 actuations of 2.5 µg] and 10 µg [2 actuations...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-001759-42 Sponsor Protocol Number: 214094 Start Date*: 2020-05-20
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease.
    Medical condition: Severe pulmonary COVID-19 related disease
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) ES (Completed) BE (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000525-32 Sponsor Protocol Number: 1199-0248 Start Date*: 2019-01-31
    Sponsor Name:Boehringer Ingelheim España, S.A.
    Full Title: An open-label extension trial of the long term safety of nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
    Medical condition: Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10066393 Respiratory bronchiolitis-associated interstitial lung disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Completed) GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000643-95 Sponsor Protocol Number: CNVA237A2206 Start Date*: 2007-06-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled, parallel group, multi-center study, to assess the safety and tolerability of 28 days treatment with NVA237 (100 or 200µg once a day) in patients with...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-002754-36 Sponsor Protocol Number: 3119002 Start Date*: 2018-05-08
    Sponsor Name:Orion Corporation
    Full Title: Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS
    Medical condition: Amyotrophic lateral sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) BE (Completed) FI (Completed) AT (Completed) ES (Completed) NL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003703-13 Sponsor Protocol Number: CQAB149B2305 Start Date*: 2007-12-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III randomized, double-blind, double dummy, placebo controlled, multicenter, 4 treatments, 3 period incomplete block crossover study to assess the efficacy and safety of indacaterol 300 µg ...
    Medical condition: moderate to severe COPD (chronic obstructive pulmonary disease)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-003938-18 Sponsor Protocol Number: BY217/M2-125 Start Date*: 2006-01-11
    Sponsor Name:Nycomed GmbH
    Full Title: Effect of roflumilast on exacerbation rate in patients with COPD. A 52 weeks, double-blind study with 500 mcg roflumilast once daily versus placebo
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-008748-26 Sponsor Protocol Number: CQAB149B2312 Start Date*: 2009-05-26
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: Estudio fase IIIb, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de 2 periodos cruzados, para evaluar el efecto de indacaterol (150 µg o.d.), en pacientes con enfermedad pulmona...
    Medical condition: Enfermedad Pulmonar Obstructiva Crónica (EPOC) de moderada a grave
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) DK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 31  32  33  34  35  36  37  38  39  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 23 09:19:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA